Tipranavir: Difference between revisions
Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or [[user talk:Che... |
changed chembl id |
||
| Line 39: | Line 39: | ||
| UNII = ZZT404XD09 |
| UNII = ZZT404XD09 |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = |
| ChEMBL = 183041 |
||
| NIAID_ChemDB = 032941 |
| NIAID_ChemDB = 032941 |
||
Revision as of 12:39, 23 January 2012
 | |
| Clinical data | |
|---|---|
| Trade names | Aptivus |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606009 |
| License data |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99.9% |
| Metabolism | Hepatic |
| Elimination half-life | 5–6 hours |
| Excretion | Fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.158.066 |
| Chemical and physical data | |
| Formula | C31H33F3N2O5S |
| Molar mass | 602.66 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer-Ingelheim under the trade name Aptivus. It is administered with ritonavir in combination therapy to treat HIV infection and is given as two 250 mg capsules together with 200 mg of ritonavir twice daily.
Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[2]
Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[3] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir can be more severe than other anti-retrovirals. Some side effects include intracranial hemorraging[citation needed], hepatitis[4], and diabetes mellitus[citation needed]. The drug has also been shown to cause increases in total cholesterol and triglycerides[citation needed].
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley M (2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir". Antiviral Res. 68 (1): 27–35. doi:10.1016/j.antiviral.2005.07.003. PMID 16122817.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release). Boehringer Ingelheim. 2008-06-24. Retrieved 2008-09-02.
- ^ "Aptivus (tipranavir) Capsules, 250 mg, Prescribing Information", Boehringer Ingelheim, 2007. Revised February 5, 2007.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |